OPDIVO®
(nivolumab)

Patient Alert Card

This card contains important information.

Please carry this card with you at all times to inform healthcare professionals that you are receiving treatment with

☐ OPDIVO® or
☐ OPDIVO® in combination with YERVOY® (ipilimumab).
Important Information for Patients

If you have any signs or symptoms, tell your doctor right away.

![Important Information]

**OPDIVO®** treatment may increase the risk of serious or even life-threatening immune-related side-effects, which may affect different parts of the body, for example:

- **Chest (heart and lungs):** breathing difficulties, cough, wheeze, chest pain, irregular heartbeat, palpitations (increased awareness of your heartbeat)

- **Gut (stomach and bowels):** diarrhoea (watery, loose or soft stools), blood or mucus in stools, dark-coloured stools, pain or tenderness in your stomach or abdominal area

- **Liver:** eye or skin yellowing (jaundice), pain on the right side of your stomach area

- **Kidney:** change in amount and/or frequency of urine

- **Hormone-producing glands (including Diabetes):** headaches, blurry or double vision, fatigue (tiredness), weight changes, behavioural changes (e.g., lower sex drive, irritability or forgetfulness), excessive thirst, increased appetite with weight loss, weakness, drowsiness, depression, irritability, feeling unwell, change in amount and/or frequency of urine

- **Skin:** rash, itching, blisters and/or peeling of the skin (possibly fatal), ulcers, dry skin, skin nodules

- **Other:** weakness, fatigue (tiredness), decreased appetite, nausea, vomiting, tingling or numbness in arms and legs, difficulty walking, fever, swollen lymph nodes, headache, seizures, stiff neck, confusion, drowsiness, muscle pain, stiffness, dark urine, eye pain or redness, blurry vision, or other vision problems
This patient is treated with **OPDIVO®** or **OPDIVO® in combination with YERVOY®**.

- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise the risk of life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the OPDIVO® Summary of Product Characteristics (SmPC) or call Medical Information on phone: 0800/0752002, email: medwiss.info@bms.com or www.bmsmedinfo.de for more information.
Doctor’s contact information